The QALY: Health Economics’ Favorite Yardstick—or a Misguided Ruler?
If you’ve ever wondered how governments decide which new drugs to fund and which to reject, chances are the
How Europe Can Compete in the Global Biotech Race: Lessons from the Capital for Cures Event Series
If biotech were a footrace, Europe would be the competitor with flawless running shoes, world-class muscle tone—and one leg
The Mansion House Accord: Reinvigorating UK Investment or Merely Rebadging the Status Quo?
In July 2023, the United Kingdom government launched the Mansion House Compact, a voluntary commitment by nine of the country’
Whither ESG? The Curious Case of Pharma's Forgotten Acronym
Ah, ESG! Not long ago, you could hardly sip your oat milk latte—or endure a quarterly earnings call—without
Health Economics: Pharma’s Favorite Crystal Ball
Health economics is to pharma what a crystal ball is to a fortune teller—draped in mystique, full of promise,
ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?
The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
In a Hole in the Budget There Lived a KOL
Not a nasty, dirty, wet hole, nor yet a humble one. This was a suite at the Four Seasons, with
The Problem with Markov Models
Markov models have become a default tool in drug development, used for modeling disease progression, treatment outcomes, and cost-effectiveness. While
AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead
Artificial intelligence has had a profound decade in biotech, advancing from a promising academic endeavor to a critical driver of
The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis
Optimism bias, the cognitive tendency to overestimate the likelihood of favorable outcomes and underestimate risks, is a pervasive issue in
